Over the past ten quarters, spanning 2023 to June 2025, Twist Bioscience Corp. (TWST) has delivered consistent revenue growth while tightening its belt on losses. With momentum building and a breakeven target on the horizon for fiscal 2026, is it time to take a closer look at the stock?
Twist Bioscience is a synthetic biology company with a disruptive DNA synthesis platform that uses proprietary technology to "write" DNA on a silicon chip, pioneering a new method of manufacturing synthetic DNA. This unique technology is used to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing or NGS, sample preparation, and antibody libraries for drug discovery and development. The synthetic DNA and synthetic DNA-based products are sold to customers across multiple industries, including healthcare, chemicals/materials, food/agriculture, and academic research, serving a global customer base of about 3,562 customers.
For comments and feedback: editorial@rttnews.com